MADISON, Wis., March 3, 2026
AI-powered oncology analytics reached a new milestone as AIQ Solutions announced that the American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code describing the analytical output of its TRAQinform IQ technology. The new code marks a significant step toward broader adoption of advanced artificial intelligence–driven cancer treatment response analysis, enabling healthcare systems and clinicians to access more precise insights into how metastatic tumors respond to therapy. By formally recognizing this innovative technology within the CPT framework, the development supports greater integration of AI-driven precision oncology tools across hospitals, cancer centers, and clinical practices.
New CPT Code Supports Advanced AI Cancer Analysis
The approval of a Category III CPT code represents an important regulatory and operational milestone for emerging healthcare technologies, particularly those driven by artificial intelligence and advanced analytics. Category III codes are designed to track the use and clinical performance of innovative medical procedures and technologies that are still gaining widespread adoption. In this case, the code recognizes the unique analytical output generated by TRAQinform IQ, an AI-powered platform developed by AIQ Solutions that evaluates heterogeneity of treatment response across multiple cancer lesions in patients with advanced metastatic disease.
Traditional imaging assessments typically evaluate tumors using broader metrics that may not fully capture how individual lesions respond to therapy. However, TRAQinform IQ provides lesion-level intelligence that identifies differences in treatment response among tumors within the same patient, offering oncologists deeper insights into patterns of resistance or effectiveness. For patients with advanced cancers, where treatment decisions are often complex and time-sensitive, this type of analysis can play a critical role in guiding therapy adjustments and improving outcomes.
Experts note that recognition through a CPT code also helps create a pathway for broader clinical adoption, as it allows healthcare providers to document and track the use of the technology in clinical practice. This recognition may also facilitate future reimbursement discussions with healthcare payers, helping expand access to precision oncology tools.
Advertisement
Precision Oncology Technology Enhances Treatment Decisions
TRAQinform IQ is designed to provide clinicians with earlier and more detailed insights into how cancer lesions respond to treatment, enabling more informed clinical decision-making. By leveraging advanced analytics and machine learning techniques, the platform analyzes imaging data to detect subtle patterns of response heterogeneity that may not be visible through conventional methods.
In metastatic cancer, individual tumors within the same patient may react differently to therapy due to genetic diversity and evolving resistance mechanisms. Understanding these differences is essential for optimizing treatment strategies, especially when determining whether to continue, modify, or change a therapy regimen. AIQ Solutions’ technology aims to address this challenge by delivering actionable insights that help oncologists better understand tumor behavior at a granular level.
Company leadership emphasized that the new CPT code underscores the clinical value of AI-driven analytics in oncology. By formally recognizing the unique analytical capabilities of TRAQinform IQ, the AMA has acknowledged the growing importance of artificial intelligence in transforming cancer care. The milestone also strengthens AIQ Solutions’ position as a leader in advanced oncology analytics, supporting its ability to expand partnerships with hospitals, research institutions, and healthcare systems.
Growing Role of AI in Oncology Innovation
Artificial intelligence is rapidly becoming a powerful tool in oncology, supporting everything from diagnostic imaging and biomarker discovery to treatment optimization and clinical decision support. The ability of AI systems to process large volumes of medical data and detect subtle patterns offers significant advantages for clinicians managing complex diseases such as metastatic cancer.
Despite the rapid growth of AI-driven healthcare technologies, formal recognition within clinical coding frameworks remains relatively rare. According to industry data, approximately 1,400 AI-enabled medical software devices have been cleared or approved by the U.S. Food and Drug Administration, yet fewer than 30 CPT codes have been issued for software-enabled procedures. This makes the recognition of AIQ Solutions’ technology particularly noteworthy within the evolving digital health landscape.
By introducing a CPT code tied to lesion-level response heterogeneity analysis, the healthcare system moves one step closer to integrating precision intelligence tools that support personalized oncology treatment strategies. Researchers and clinicians believe that continued advancements in AI-driven analytics could significantly improve how physicians evaluate treatment effectiveness, monitor disease progression, and identify resistance patterns earlier in the treatment process.
As the healthcare industry increasingly embraces digital innovation, the approval of this new CPT code signals growing acceptance of artificial intelligence as a core component of modern cancer care, helping clinicians deliver more informed, data-driven decisions for patients facing advanced metastatic disease.
z
Source: AIQ Solutions press release
